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Does size matter? Addressing pack size  
and antibiotic duration
therefore be influenced by not only the dose 
prescribed but also the inherent characteristics of 
the antibiotic.7
Judicious antibiotic use needs to balance prescribing 
for too short a period (causing treatment failure, 
delayed return to health or the development of 
complications) with overprescribing which increases 
the risk of resistance, non-adherence, adverse effects 
and cost. Sub-therapeutic antibiotic concentrations 
can encourage antibiotic-resistant bacteria.8 Other 
considerations when prescribing include the 
characteristics of the infecting organism, the patient’s 
immune status and the bacterial gene pool.
While clinical evidence favours prolonged treatment to 
prevent the relapse of conditions such as enterococcal 
endocarditis, only short courses are needed for 
uncomplicated urinary tract infections in women. 
Evaluation of 13 meta-analyses to optimise antimicrobial 
duration in common bacterial infections determined 
that the duration of therapy could be shortened in 
most of these infections by at least three days without 
compromising patient outcomes.9 However, for many 
infections managed in the community, the optimum 
treatment duration is unknown.
To improve the likelihood of success in clinical trials, 
a longer duration of antibiotics than the theoretical 
minimum may be used. Only after establishing 
efficacy are equivalence trials of shorter durations 
conducted. As non-inferiority trials require large 
numbers of patients, cost drives trial design towards 
single rather than multiple duration arms. Several 
pharmacokinetic and pharmacodynamic models have 
been proposed for duration-randomised trials to 
overcome cost as a barrier.10 To extend the lifespan of 
antibiotics there needs to be collaboration between 
researchers, clinicians and the pharmaceutical 
industry to conduct equivalence trials. These are 
needed to determine the optimal minimum antibiotic 
regimen for common infections in Australia.
Ambiguity about the optimal duration of treatment 
for a particular indication contributes to uncertainty 
about how many doses to put in a pack. However, 
pack size heavily influences the duration of use. It will 
continue to do so while consumers are given advice to 
‘complete the antibiotic course’.
A 2015 analysis of published data on the most 
commonly prescribed antibiotics in Australian primary 
In Australia, most antibiotics are prescription-
only so prescribers are the custodians of judicious 
use. They need to balance their concerns about 
antibiotic resistance with their responsibility for 
individual patient management. Prescribing with no 
clinical indication, inappropriate drug choice, and 
suboptimal dosing and duration can all contribute to 
antimicrobial resistance.1,2 Clinical practice guidelines 
are therefore important for improving the quality and 
cost-effectiveness of infectious disease management. 
However, subtle factors such as the size of antibiotic 
packs could impact on judicious antibiotic use.
Antibiotic prescribing in primary care is largely 
empiric and symptom based. Antibiotics are usually 
started without microbiological testing. Clinical 
practice guidelines usually focus on antibiotic choice, 
with a recommended dose, frequency and duration, 
but have limited advice on resistance patterns.3 
Optimising the dose and duration of antibiotic 
treatment could simultaneously minimise both the 
symptomatic period and the selection pressure 
for resistance.4
Clinical practice guideline recommendations differ 
globally, particularly for the duration of antibiotic 
therapy.5,6 When two UK guidelines for community-
acquired pneumonia were critically assessed, there 
was a key difference of 2–3 days in the recommended 
course of antibiotics for infections of low–moderate 
severity.5 Similarly, there were major differences in 
the recommended treatment duration for paediatric 
infections across seven reputable clinical practice 
guidelines.6 The fact that recommendations about 
the duration of therapy are based more on expert 
opinion than strong scientific evidence is not widely 
appreciated by clinicians.
It is clear that no ‘one-size-fits-all’ for the length of 
an antibiotic course.4 Infection resolution requires 
the antimicrobial to reach and remain at the site of 
infection in a sufficient concentration for a sufficient 
time. Concentration-dependent antibiotics such 
as aminoglycosides display maximal bactericidal 
activity at high concentrations, even if these 
concentrations are maintained for a relatively 
short time. In contrast, antibiotics displaying time-
dependent activity, for example beta-lactams, 
require free drug at the infection site to be above 
the minimum inhibitory concentration or breakpoint 
concentration for a longer time. Duration can 
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care and their most common indications found a 
clear mismatch between the recommended treatment 
duration in clinical practice guidelines and the 
pharmaceutical industry packaging.11 Of 32 common 
prescribing scenarios, 10 had doses in surplus and 18 
had a shortfall, leaving only four where the pack size 
matched the recommended duration. In only two cases 
was a shortfall addressed by a repeat prescription.
Any mismatch between pack size and doses 
consumed might contribute to leftover antibiotics in 
the community. If these antibiotics are subsequently 
taken by the patient or someone else, it would 
contribute to potentially inappropriate use and, 
thereby, resistance. Alternatively, unused antibiotics 
could be discarded into the environment (landfill or 
waste water) which may facilitate the development or 
proliferation of resistant strains of bacteria.12
While solutions are not obvious, we must be willing 
to try strategies to reduce the mismatch between 
guidelines and antibiotic packaging. Regulations 
could require the industry to package antibiotics in 
accordance with clinical practice guidelines. While 
multiple pack sizes would increase costs, government 
incentives for the production of small packs could 
increase dispensing flexibility and minimise waste.
Prescribing software could improve adherence to 
clinical practice guidelines by commencing with 
the intended indication instead of the antibiotic. 
The indication would activate consensus regimens 
supported by evidence (or lack thereof). Prescriptions 
would not be printed until dose, frequency and 
importantly duration were entered, overriding the 
default pack and calculating the required quantity. 
Pharmacists would require corresponding dispensing 
software. They would also need to spend more time 
to implement safety strategies to prevent the reuse of 
broken packs with varying expiry dates.
Clinicians and the public should be informed that 
completing the pack is no longer supported by 
evidence and that resistance is primarily due to 
overuse. Patients should be empowered to stop their 
antibiotic after a specified minimum number of days 
or when they feel better (whichever comes first) 
and to return any unused doses for safe disposal to 
the pharmacy where the medicine was dispensed.13 
These and similar strategies warrant discussion to 
potentially extend the lifespan of antibiotics without 
compromising patient care. 
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